<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561220</url>
  </required_header>
  <id_info>
    <org_study_id>COMPPARE</org_study_id>
    <secondary_id>PCORI-6312</secondary_id>
    <secondary_id>IRB201801001</secondary_id>
    <secondary_id>OCR17881</secondary_id>
    <nct_id>NCT03561220</nct_id>
  </id_info>
  <brief_title>A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer</brief_title>
  <acronym>COMPPARE</acronym>
  <official_title>A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a large, prospective, pragmatic, controlled comparison of patient-centric
      outcomes [quality of life (QOL), toxicity, and disease control] between parallel cohorts of
      men with prostate cancer treated simultaneously at proton therapy facilities and at
      geographically similar conventional (photon-based) radiation facilities using
      intensity-modulated radiation therapy (IMRT) techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a large, prospective, pragmatic, controlled comparison of patient-centric
      outcomes [quality of life (QOL), toxicity, and disease control] between parallel cohorts of
      men with prostate cancer treated simultaneously at proton therapy facilities and at
      geographically similar conventional (photon-based) radiation facilities using
      intensity-modulated radiation therapy (IMRT) techniques. Pre-specified subset comparators
      include a randomized comparison of standard fractionation and moderate hypofractionation dose
      schemes within the proton therapy cohort. In addition, analysis of heterogeneous treatment
      effects (HTE) will include a comparison of outcomes by race (Black vs. White), comorbidity
      score (0 vs. 1+), age (â‰¤65 vs. &gt;65), and prostate cancer aggressiveness (low, intermediate,
      and high risk) for all endpoints.

      All interventions will be standard of care (SOC) radiation strategies using either IMRT or
      proton therapy. All patient-reported QOL, patient-scored and patient-reported toxicity, and
      disease control assessments will be SOC. Participants will also complete pretreatment surveys
      regarding demographic data, personal treatment goals, factors affecting treatment
      decision-making, and sources of information used in treatment selection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bowel, urinary, and sexual dysfunction Expanded Prostate Cancer Index Composite (EPIC) domain scores</measure>
    <time_frame>2-years after the end of radiation therapy</time_frame>
    <description>EPIC assesses the disease-specific aspects of prostate cancer and its therapies and comprises four summary domains (Urinary, Bowel, Sexual and Hormonal). Factor analysis supports dividing the Urinary Domain Summary Score into two distinct Incontinence and Irritative/Obstructive subscales. In addition, each Domain Summary Score has measurable Function Subscale and Bother Subscale components. Response options for each EPIC item form a Likert scale, and multi-item scale scores are components. Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better HRQOL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 2 or higher toxicity for each adverse event assessed by CTCAE</measure>
    <time_frame>2-years after the end of radiation therapy</time_frame>
    <description>The NCI Common Terminology Criteria for Adverse Events v5.0 is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 2 or higher toxicity for each adverse event assessed by PRO-CTCAE.</measure>
    <time_frame>2-years after the end of radiation therapy</time_frame>
    <description>PRO-CTCAE responses are scored from 0 to 4, and there are as yet no standardized scoring rules for how to combine attributes into a single score or how best to analyse PRO-CTCAE data longitudinally. PRO-CTCAE scores for each attribute (frequency, severity and/or interference) should be presented descriptively (e.g. summary statistics or graphical presentations). CTCAE grades for the corresponding time period should be presented in conjunction with PRO-CTCAE scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from biochemical progression using PSA results.</measure>
    <time_frame>3-years after the end of radiation therapy</time_frame>
    <description>Biochemical failure is defined as a sustained rise in PSA of 2 ng/mL or more above the nadir (the lowest PSA level after radiotherapy).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>IMRT (Photon)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As this trial is pragmatic, all treatment will be standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proton Therapy Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As this trial is pragmatic, all treatment will be standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Proton Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>78.0 Gy (RBE) in 39 fractions. This is Arm 1 of the embedded randomized trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypofractionated Proton therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60.0 Gy (RBE) in 20 fractions This is Arm 2 of the embedded randomized trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard of Care IMRT (Photon)</intervention_name>
    <description>As this trial is pragmatic, all treatment will be standard of care.</description>
    <arm_group_label>IMRT (Photon)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard of Care Proton Therapy</intervention_name>
    <description>As this trial is pragmatic, all treatment will be standard of care.</description>
    <arm_group_label>Proton Therapy Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Arm 1: Standard Proton Therapy</intervention_name>
    <description>78.0 Gy (RBE) in 39 fractions</description>
    <arm_group_label>Standard Proton Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Arm 2: Hypofractionated Proton Therapy</intervention_name>
    <description>60.0 Gy (RBE) in 20 fractions</description>
    <arm_group_label>Hypofractionated Proton therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of adenocarcinoma of the prostate.

          -  Localized prostate cancer, as confirmed by staging with PSA, biopsy, Gleason score,
             DRE, and clinical stage.

          -  Very low-risk, Low-risk, intermediate-risk, or high-risk disease based on NCCN
             Prostate Cancer Risk Group Guidelines1 and Joint AUA/ASTRO/SUO Guidelines.51

          -  If patient has high-risk disease, nuclear medicine bone imaging must be performed to
             document the absence of overt metastatic disease in bones.

          -  Candidate for definitive prostate radiotherapy (either IMRT or proton).

          -  If patient is to be treated with IMRT, all treatment must be planned with IMRT; if
             patient is to be treated with protons, all treatment must be planned with protons
             (including pelvic nodes if treated).

          -  No previous prostate cancer treatment with the exception of ADT according to NCCN
             guidelines.

          -  30-85 years of age at the time of consent with a life expectancy estimation (LEE) of
             â‰¥8 years.

          -  ECOG/Zubrod Performance Status 0 - 2.

        Exclusion Criteria:

          -  Findings of metastatic disease (nodal or distant, N1 or M1).

          -  Very high-risk prostate cancer based on NCCN Prostate Cancer Risk Group Guidelines1
             and Joint AUA/ASTRO/SUO Guidelines.51

          -  Prior prostate surgical procedure

          -  History of invasive rectal malignancy or other pelvic malignancy, regardless of
             disease-free interval.

          -  Prior pelvic RT for any reason.

          -  Documented lack of psychological ability or general health permitting completion of
             the study requirements and required follow-up.

          -  Documented diminished capacity to understand the risks and benefits of participation
             in research and to autonomously provide informed consent.

        In addition, because the embedded randomized controlled trial compares fractionation
        schemes, patients who are receiving pelvic node irradiation may not be enrolled on the
        randomized controlled trial, as well as, Gleason 5+4 or 5+5 are not eligible .
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy P. Mendenhall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>COMPPARE Study Team</last_name>
    <phone>904-588-1800</phone>
    <email>comppare-admin@ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew McDonald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shona Dougherty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brent Rose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Proton Therapy Treatment Center - Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>800-776-8667</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sutter Health</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Protons Cancer Therapy Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology Davis Cancer Pavilion</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alesa Flewellen, BS</last_name>
      <phone>352-265-8094</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Proton Therapy Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Intake Coordinator</last_name>
      <phone>877-686-6009</phone>
    </contact>
    <investigator>
      <last_name>Nancy P Mendenhall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ackerman Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>904-953-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alan Pollack</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Health UF Health Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute - Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>833-377-6866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Proton Center</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-887-5807</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Lawrence</city>
        <state>Kansas</state>
        <zip>66045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xinglei Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Willis-Knighton Medical Center PTC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Durci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>College Park</city>
        <state>Maryland</state>
        <zip>20742</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System</name>
      <address>
        <city>Mankato</city>
        <state>Minnesota</state>
        <zip>56001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>507-538-3270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S Lee Kling Proton Therapy Center - Washington University Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-286-1222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ProCure Proton Therapy Center</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Proton Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Silvia Formenti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Univeristy of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC- Rex Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical PTC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rahul Tendulkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tyler Gunter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arthur Hung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania--Penn Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neha Vapiwal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Provision CARES Proton Therapy Center Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Center for Proton Therapy</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Showalter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hampton University Proton Therapy Institute</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Care Alliance/University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System-Franciscan Healthcare</name>
      <address>
        <city>Sparta</city>
        <state>Wisconsin</state>
        <zip>54656</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>NCCN Clinical Practical Guidelines in Oncology: Prostate Cancer. Version 2. 2018.</citation>
  </reference>
  <reference>
    <citation>AJCC Cancer Staging Manual. 8th ed. Cham, Switzerland: Springer International Publishing; 2017.</citation>
  </reference>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.</citation>
    <PMID>28055103</PMID>
  </reference>
  <reference>
    <citation>U.S. Preventive Services Task Force. Draft Recommendation Statement: Prostate Cancer: Screening. April 2017; https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementDraft/prostate-cancer-screening1. Accessed May 8, 2017.</citation>
  </reference>
  <reference>
    <citation>Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol. 2009 Aug 20;27(24):3916-22. doi: 10.1200/JCO.2008.18.6486. Epub 2009 Jul 20.</citation>
    <PMID>19620493</PMID>
  </reference>
  <reference>
    <citation>Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008 Mar 20;358(12):1250-61. doi: 10.1056/NEJMoa074311.</citation>
    <PMID>18354103</PMID>
  </reference>
  <reference>
    <citation>Stokes ME, Ishak J, Proskorovsky I, Black LK, Huang Y. Lifetime economic burden of prostate cancer. BMC Health Serv Res. 2011 Dec 28;11:349. doi: 10.1186/1472-6963-11-349.</citation>
    <PMID>22204308</PMID>
  </reference>
  <reference>
    <citation>Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995 Aug;33(8):828-41.</citation>
    <PMID>7637404</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.</citation>
    <PMID>21296855</PMID>
  </reference>
  <reference>
    <citation>Gray PJ, Lin CC, Cooperberg MR, Jemal A, Efstathiou JA. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol. 2017 May;71(5):729-737. doi: 10.1016/j.eururo.2016.08.047. Epub 2016 Sep 3.</citation>
    <PMID>27597241</PMID>
  </reference>
  <reference>
    <citation>Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.</citation>
    <PMID>27253694</PMID>
  </reference>
  <reference>
    <citation>Chamie K, Williams SB, Hu JC. Population-Based Assessment of Determining Treatments for Prostate Cancer. JAMA Oncol. 2015 Apr;1(1):60-7. doi: 10.1001/jamaoncol.2014.192.</citation>
    <PMID>26182305</PMID>
  </reference>
  <reference>
    <citation>Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.</citation>
    <PMID>27626136</PMID>
  </reference>
  <reference>
    <citation>Zietman A. Proton beam and prostate cancer: An evolving debate. Rep Pract Oncol Radiother. 2013 Jul 3;18(6):338-42. doi: 10.1016/j.rpor.2013.06.001. Review.</citation>
    <PMID>24416575</PMID>
  </reference>
  <reference>
    <citation>Wisenbaugh ES, Andrews PE, Ferrigni RG, Schild SE, Keole SR, Wong WW, Vora SA. Proton beam therapy for localized prostate cancer 101: basics, controversies, and facts. Rev Urol. 2014;16(2):67-75.</citation>
    <PMID>25009446</PMID>
  </reference>
  <reference>
    <citation>Vargas C, Fryer A, Mahajan C, Indelicato D, Horne D, Chellini A, McKenzie C, Lawlor P, Henderson R, Li Z, Lin L, Olivier K, Keole S. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):744-51. Epub 2007 Sep 27.</citation>
    <PMID>17904306</PMID>
  </reference>
  <reference>
    <citation>Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, Bortfeld TR, Zietman AL, Delaney TF, Shipley WU. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):444-53. Epub 2007 May 21.</citation>
    <PMID>17513063</PMID>
  </reference>
  <reference>
    <citation>Friedland W, Schmitt E, KundrÃ¡t P, Dingfelder M, Baiocco G, Barbieri S, Ottolenghi A. Comprehensive track-structure based evaluation of DNA damage by light ions from radiotherapy-relevant energies down to stopping. Sci Rep. 2017 Mar 27;7:45161. doi: 10.1038/srep45161.</citation>
    <PMID>28345622</PMID>
  </reference>
  <reference>
    <citation>Winter M, Dokic I, Schlegel J, Warnken U, Debus J, Abdollahi A, SchnÃ¶lzer M. Deciphering the Acute Cellular Phosphoproteome Response to Irradiation with X-rays, Protons and Carbon Ions. Mol Cell Proteomics. 2017 May;16(5):855-872. doi: 10.1074/mcp.M116.066597. Epub 2017 Mar 16.</citation>
    <PMID>28302921</PMID>
  </reference>
  <reference>
    <citation>Grosse N, Fontana AO, Hug EB, Lomax A, Coray A, Augsburger M, Paganetti H, Sartori AA, Pruschy M. Deficiency in homologous recombination renders Mammalian cells more sensitive to proton versus photon irradiation. Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):175-81. doi: 10.1016/j.ijrobp.2013.09.041. Epub 2013 Nov 13.</citation>
    <PMID>24239385</PMID>
  </reference>
  <reference>
    <citation>Tommasino F, Durante M. Proton radiobiology. Cancers (Basel). 2015 Feb 12;7(1):353-81. doi: 10.3390/cancers7010353. Review.</citation>
    <PMID>25686476</PMID>
  </reference>
  <reference>
    <citation>Bryant C, Smith TL, Henderson RH, Hoppe BS, Mendenhall WM, Nichols RC, Morris CG, Williams CR, Su Z, Li Z, Lee D, Mendenhall NP. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):422-434. doi: 10.1016/j.ijrobp.2016.02.038. Epub 2016 Feb 16.</citation>
    <PMID>27084658</PMID>
  </reference>
  <reference>
    <citation>Mendenhall NP, Hoppe BS, Nichols RC, Mendenhall WM, Morris CG, Li Z, Su Z, Williams CR, Costa J, Henderson RH. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):596-602. doi: 10.1016/j.ijrobp.2013.11.007.</citation>
    <PMID>24521677</PMID>
  </reference>
  <reference>
    <citation>Waddle MR, Sio TT, Van Houten HK, Foote RL, Keole SR, Schild SE, Laack N, Daniels TB, Crown W, Shah ND, Miller RC. Photon and Proton Radiation Therapy Utilization in a Population of More Than 100 Million Commercially Insured Patients. Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1078-1082. doi: 10.1016/j.ijrobp.2017.07.042. Epub 2017 Aug 2.</citation>
    <PMID>28939229</PMID>
  </reference>
  <reference>
    <citation>Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013 Jan 31;368(5):436-45. doi: 10.1056/NEJMoa1209978.</citation>
    <PMID>23363497</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Proton Radiation</keyword>
  <keyword>Photon Radiation</keyword>
  <keyword>Cancer of the Prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

